ArticleInfection and drug resistance2026
The Predictive Value of Dynamic Changes in Procalcitonin and C-Reactive Protein in Evaluating Response of Patients with Pulmonary Tuberculosis in the Early Treatment.
Article in Infection and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To explore the predictive value of dynamic changes in procalcitonin (PCT) and C-reactive protein (CRP) in evaluating early treatment response in patients with pulmonary tuberculosis (PTB). Methods: A retrospective study was conducted on 168 PTB patients from June 2022 to June 2024. Based on early treatment efficacy, patients were divided into an effective group (136 cases, 80.95%) and an ineffective group (32 cases, 19.05%). Clinical data of the two groups were compared, and variables showing significant differences were analyzed using logistic regression analysis. The predictive value was evaluated through ROC curves, nomograms, and calibration curves. The dynamic changes in PCT and CRP and their correlations with treatment outcomes were also analyzed. Results: Significant differences were observed between the ineffective and effective groups in terms of the number of lung fields involved and pulmonary cavitary lesions (P < 0.05). Additionally, baseline levels of PCT, CRP and IL-6 were significantly higher in the ineffective group than in the effective group (P < 0.05). The number of lung fields involved, pulmonary cavitary lesions, PCT, CRP, and IL-6 were identified as independent factors influencing early treatment efficacy in PTB patients. PCT, CRP, and IL-6 demonstrated high predictive value for treatment outcomes. On days 1, 5, and 7 after treatment, PCT and CRP levels were significantly lower in the effective group than in the ineffective group (P < 0.05), with the most pronounced difference observed on day 1. Greater reductions in PCT and CRP levels were associated with better treatment outcomes and larger lesion absorption area (P < 0.05). Conclusion: The number of lung fields involved, pulmonary cavitary lesions, PCT, CRP, and IL-6 all influence early treatment efficacy in PTB patients. Among these, dynamic changes in PCT and CRP exhibit high predictive value, providing a reliable basis for clinical assessment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.